Hematopoietic stem cell transplantation is a procedure in which multipotent hematopoietic stem cells sourced from peripheral blood cells, bone marrow or umbilical cord blood are transplanted into a patient. Hematopoietic stem cell transplantation is commonly used in the treatment of lymphoma (Hodgkin, Non-Hodgkin), leukemia, multiple myeloma, thalassemia, sickle cell anemia, and osteoporosis. It includes two transplantation sources namely, autologous that uses stem cells from the patient’s own body and allogeneic that sources stem cells from a donor’s body. According to World Health Organization (WHO), over 50,000 hematopoietic stem cell transplantation procedures are carried out globally, every year and this number is expected to increase over the years.

Rising incidence of leukemia and lymphoma and continuous research on hematopoietic stem cells are expected to drive market growth

As per 2017 report by Leukemia and Lymphoma Society, the U.S. alone is expected to account for a prevalence of 8,16,834 and incidence of 80,500 for lymphoma. Increasing rate of incidence is in turn, expected to increase the demand for hematopoietic stem cell transplantation thus, propelling growth of the hematopoietic stem cell transplantation (HSCT) market. Increasing awareness about stem cell therapies among the population is also expected to propel growth of the hematopoietic stem cell transplantation market. As per survey by World Network for Blood and Marrow Transplantation (WBMN), around one million hematopoietic stem cell transplantation procedures were performed during 2006 to 2014, which indicates potential opportunities for market players.

Request For A Sample Copy Of This Research Report: https://www.coherentmarketinsights.com/insight/request-sample/1250

Global Hematopoietic Stem Cell Transplantation Market Taxonomy

On the basis of indication: Leukemia, Lymphatic disorder, Myeloma, Other non-malignant disorders (thalassemia, sickle cell anemia, Osteoporosis, Immunodeficiency syndrome)

On the basis of application: Peripheral blood cells, Bone marrow, Umbilical cord blood

Increasing adoption of the growing trend of personalized medicine is expected to drive growth of the hematopoietic stem cells transplantation market. A collaborative research study on hematopoietic stem cell transplantation initiated by World Network for Blood and Marrow Transplantation (WBMN) in 2013 in the domain of promotion of access to hematopoietic stem cell transplantation, developed a donation guidance document, technical and scientific input on safety, and quality of HSCT as mentioned in annual report of the WBMN.

In March 2017, Gilead Sciences announced the acquisition of Kite Pharma, which produces products such as Axi-cel to treat non-Hodgkin lymphoma. Plasticell, which specializes in the development of stem cell technologies and cell-based therapies, announced entering into an agreement with Nan yang Technological University (NTU) in Singapore on March 2017, to advance its therapeutic stem cell pipeline. Plasticell also announced collaboration with Anthony Nolan, a research organization in blood cancer, to progress clinical development of Plasticell’s ex vivo expanded cord blood-derived hematopoietic stem cell product in December 2017. Also, GE Healthcare announced the introduction of Thaw CB1000, for thawing large volumes of cell therapies cryopreserved in cryo-bags majorly intended for use in research laboratory, in September 2017.

Important players present in the hematopoietic stem cell transplantation market

Major players operating in the hematopoietic stem cell transplantation market include Pluristem Therapeutics Inc., CellGenix Technologie Transfer GmbH, Kite Pharma Inc., Regen Biopharma Inc., BiolineRx, Cynata Therapeutics, Lonza Group Ltd, Cesca Therapeutics Inc, TiGenix N.V., Escape Therapeutics Inc., Bluebird Bio, and Cellular Dynamics International.

Click To Read More On Hematopoietic Stem Cell Transplantation (HSCT) Market

Also, Coherent Market Insights has a proprietary database of pipeline biologics and biosimilars, called PHASE-XS. This database provides analytical data in addition to the clinical information of ongoing trials for biologics and biosimilars. An amalgamation of more than 30 parameters, PHASE-XS helps biotechnology and pharmaceutical companies to analyze the market trend, competition, and market potential. For more information or to access this database, kindly click on the below link or contact at [email protected]

https://www.coherentmarketinsights.com/phase-xs/

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.